SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.67-10.7%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert S. who wrote (10434)6/13/1999 9:03:00 PM
From: Robert K.  Read Replies (1) of 17367
 
RobertS>I can generally agree with what you said. You surprised me.
>
First of all let me say that I wouldnt be so sure that bpi21 is limitied to gram negatives.
Especially considering the adjunct uses. But the answer to your question is I think a bit more complex. The answer lies in lbp IMO. Xoma is not targeting gram negs but instead high lbp conditions. Lbp is abnormally high in many disease states.
Lbp attached to cd14 and kicks off the inflamatory cascade
which includes TNF, IL-1, IL-6, IL-8 (remember enbril & antril).
In addition we have adhesion molecules, and coagulation cascades kicking in. Soooooooooooo, if lbp is the trigger and
bpi21 takes the available cd14 sites away from lbp then NO
kick-off. How simple. ALSO >do not forget HOROWITZ paper in 95 that discusses how lbp potentiates bpi up to 10,000 fold.
That said> use bpi21 in high lbp disease states and you have a plan IMO.
Please reference this site>http://www.xoma.com/coinfo/prodshts/pr_lbp.html
Please be aware that I DO NOT KNOW what I am talking about, and that much of what I said is GUESSWORK on my part. None of it may be factual. Consider all as worthlessopinion.
All disclaimers always apply to all my notes, here and elsewhere,
past ,present, and future. Never invest based on what I say.
(standard K disclaimer)
Hope that helps.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext